[1] Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos Trans Roy Soc B Biol Sci 2001;356(1416):1861 − 70. http://dx.doi.org/10.1098/rstb.2001.0999CrossRef
[2] WHO. Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. https://www.who.int/influenza/vaccines/virus/recommendations/202002_recommendation.pdf?ua=1. [2020-2-28].https://www.who.int/influenza/vaccines/virus/recommendations/202002_recommendation.pdf?ua=1
[3] WHO. Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season. https://www.who.int/influenza/vaccines/virus/recommendations/202009_recommendation.pdf?ua=1. [2020-9-25].https://www.who.int/influenza/vaccines/virus/recommendations/202009_recommendation.pdf?ua=1
[4] WHO. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase Inhibitor (NAI). https://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/. [2020-10-13].https://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/
[5] Yang J, Huang WJ, Cheng YH, Chen T, Tan MJ, Guo Q, et al. Different starting dominant strain of seasonal influenza in china and other neighboring asian countries in 2019?2020 winter season. China CDC Wkly 2020;2(4):57 − 60. http://dx.doi.org/10.46234/ccdcw2020.016CrossRef
[6] WHO. Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation.pdf?ua=1. [2019-2-21].https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation.pdf?ua=1
[7] Xu XY, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, et al. Update: influenza activity in the united states during the 2018-19 season and composition of the 2019-20 influenza vaccine. MMWR Morb Mortal Wkly Rep 2019;68(24):544 − 51. http://dx.doi.org/10.15585/mmwr.mm6824a3CrossRef
[8] Klein EY, Serohijos AWR, Choi JM, Shakhnovich EI, Pekosz A. Influenza a H1N1 pandemic strain evolution-divergence and the potential for antigenic drift variants. PLoS One 2014;9(4):e93632. http://dx.doi.org/10.1371/journal.pone.0093632CrossRef
[9] Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang WJ, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral Res 2017;146:12 − 20. http://dx.doi.org/10.1016/j.antiviral.2017.08.004CrossRef